Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Renxian Xie

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Critical Reviews in Oncology/Hematology|June 26, 2026
Anti-EGFR Therapy Combined with Immune Checkpoint Inhibitors in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: Current Landscape and Future DirectionsYong Gan, Zhining Yang, Yang Xu, et al.
Frontiers in Oncology|February 12, 2024
Current and future on definitive concurrent chemoradiotherapy for inoperable locally advanced esophageal squamous cell carcinomaRenxian Xie, Qingxin Cai, Tong Chen, et al.
Frontiers in Pharmacology|February 23, 2026
Heart failure induced by cancer therapies: focus on targeted agents, mechanisms, risk prediction, and clinical managementLifeng Xiao, Xiaoluan Lin, Zhining Yang, et al.
Frontiers in Pharmacology|October 13, 2023
Effectiveness and safety of pelareorep plus chemotherapy versus chemotherapy alone for advanced solid tumors: a meta-analysisRenxian Xie, Hongxin Huang, Tong Chen, et al.
Critical Reviews in Oncology/Hematology|July 2, 2026
Neoadjuvant Immunotherapy in Melanoma: From Pathologic Response to Response-Adapted ManagementXiaohuan Long, Tao Wu, Yuhang Hou, et al.
Frontiers in Pharmacology|February 20, 2026
Immunotherapy-related cardiovascular toxicity: from mechanisms to managementLifeng Xiao, Weitong Liu, Yanchen Ji, et al.
Plos One|March 25, 2025
A Comparison of neoadjuvant chemotherapy and concurrent chemoradiotherapy for for FIGO 2018 stage IB3/IIA2 Cervical squamous cell carcinoma: Long-term efficacy and safety in a resource-limited settingRenxian Xie, Keyan Xie, Xiaoluan Lin, et al.
Frontiers in Immunology|July 24, 2025
Immunosuppressive mechanisms and therapeutic targeting of regulatory T cells in ovarian cancerJing Li, Haojun Huang, Renxian Xie, et al.
Journal of Stomatology, Oral and Maxillofacial Surgery|December 7, 2025
Nasal irrigation reduces radiation-induced rhinosinusitis in nasopharyngeal carcinoma treated with volumetric modulated arc therapyJiarong Li, Yanchen Ji, Zhining Yang, et al.
Frontiers in Oncology|February 4, 2025
Hippocampus-sparing volume-modulated arc therapy in patients with World Health Organization grade II glioma: a feasibility studyRenxian Xie, Hongxin Huang, Qingxin Cai, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Critical Reviews in Oncology/Hematology|June 26, 2026
Anti-EGFR Therapy Combined with Immune Checkpoint Inhibitors in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: Current Landscape and Future DirectionsYong Gan, Zhining Yang, Yang Xu, et al.
Frontiers in Oncology|February 12, 2024
Current and future on definitive concurrent chemoradiotherapy for inoperable locally advanced esophageal squamous cell carcinomaRenxian Xie, Qingxin Cai, Tong Chen, et al.
Frontiers in Pharmacology|February 23, 2026
Heart failure induced by cancer therapies: focus on targeted agents, mechanisms, risk prediction, and clinical managementLifeng Xiao, Xiaoluan Lin, Zhining Yang, et al.
Frontiers in Pharmacology|October 13, 2023
Effectiveness and safety of pelareorep plus chemotherapy versus chemotherapy alone for advanced solid tumors: a meta-analysisRenxian Xie, Hongxin Huang, Tong Chen, et al.
Critical Reviews in Oncology/Hematology|July 2, 2026
Neoadjuvant Immunotherapy in Melanoma: From Pathologic Response to Response-Adapted ManagementXiaohuan Long, Tao Wu, Yuhang Hou, et al.
Frontiers in Pharmacology|February 20, 2026
Immunotherapy-related cardiovascular toxicity: from mechanisms to managementLifeng Xiao, Weitong Liu, Yanchen Ji, et al.
Plos One|March 25, 2025
A Comparison of neoadjuvant chemotherapy and concurrent chemoradiotherapy for for FIGO 2018 stage IB3/IIA2 Cervical squamous cell carcinoma: Long-term efficacy and safety in a resource-limited settingRenxian Xie, Keyan Xie, Xiaoluan Lin, et al.
Frontiers in Immunology|July 24, 2025
Immunosuppressive mechanisms and therapeutic targeting of regulatory T cells in ovarian cancerJing Li, Haojun Huang, Renxian Xie, et al.
Journal of Stomatology, Oral and Maxillofacial Surgery|December 7, 2025
Nasal irrigation reduces radiation-induced rhinosinusitis in nasopharyngeal carcinoma treated with volumetric modulated arc therapyJiarong Li, Yanchen Ji, Zhining Yang, et al.
Frontiers in Oncology|February 4, 2025
Hippocampus-sparing volume-modulated arc therapy in patients with World Health Organization grade II glioma: a feasibility studyRenxian Xie, Hongxin Huang, Qingxin Cai, et al.
Pageof 2